Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 07 Feb 2025 Status changed from recruiting to completed.
- 15 Sep 2022 Status changed from not yet recruiting to recruiting.
- 28 Jun 2022 Planned initiation date changed from 30 May 2022 to 30 Jul 2022.